MXPA03008582A - Agentes y metodos para tratamiento de cancer. - Google Patents

Agentes y metodos para tratamiento de cancer.

Info

Publication number
MXPA03008582A
MXPA03008582A MXPA03008582A MXPA03008582A MXPA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A MX PA03008582 A MXPA03008582 A MX PA03008582A
Authority
MX
Mexico
Prior art keywords
cancer
agents
treatment
methods
Prior art date
Application number
MXPA03008582A
Other languages
English (en)
Inventor
Karen Seibert
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of MXPA03008582A publication Critical patent/MXPA03008582A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
MXPA03008582A 2001-03-23 2002-03-21 Agentes y metodos para tratamiento de cancer. MXPA03008582A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27851201P 2001-03-23 2001-03-23
US09/961,969 US7012098B2 (en) 2001-03-23 2001-09-24 Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
PCT/US2002/008938 WO2002076395A2 (en) 2001-03-23 2002-03-21 Agents and methods for treatment of cancer

Publications (1)

Publication Number Publication Date
MXPA03008582A true MXPA03008582A (es) 2003-12-08

Family

ID=26959136

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03008582A MXPA03008582A (es) 2001-03-23 2002-03-21 Agentes y metodos para tratamiento de cancer.

Country Status (8)

Country Link
US (1) US7012098B2 (es)
EP (1) EP1463495A4 (es)
JP (1) JP2005500259A (es)
AU (1) AU2002248693A2 (es)
CA (1) CA2441394A1 (es)
EA (1) EA200300934A1 (es)
MX (1) MXPA03008582A (es)
WO (1) WO2002076395A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100588647C (zh) * 2002-08-23 2010-02-10 法玛西雅公司 (2s,5z)-2-氨基-7-(乙亚胺酰基氨基)-2-甲基庚-5-烯酸的结晶固体形式
ATE353954T1 (de) * 2002-10-11 2007-03-15 Sentoclone Therapeutics Ab Immuntherapie für krebs
US20090214618A1 (en) 2005-05-27 2009-08-27 Schoenfisch Mark H Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
WO2007071389A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating disseminated cancer
WO2007071410A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating urinary bladder cancer
WO2007071388A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer
WO2007071390A1 (en) * 2005-12-21 2007-06-28 Sentoclone Ab Method for treating malignant melanoma
US7951365B2 (en) * 2007-06-27 2011-05-31 Deifiera Falun Ab Method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with specific cancer types
JP2011528326A (ja) * 2008-07-18 2011-11-17 セントクローネ インターナショナル エービー インビトロ拡大されたｔリンパ球及びガン治療に適切な血管形成インヒビターを含む組成物
EP2334279A4 (en) * 2008-10-16 2013-03-20 Novan Inc STAIN OXIDE RELEASING PARTICLES FOR MOUTH CARE APPLICATIONS
BR112012003792B1 (pt) 2009-08-21 2020-05-19 Novan Inc composição tópica, e, uso da composição tópica
WO2011022680A2 (en) 2009-08-21 2011-02-24 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
US20110086234A1 (en) * 2009-10-13 2011-04-14 Nathan Stasko Nitric oxide-releasing coatings
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
EP2681286B1 (en) 2011-02-28 2018-08-15 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
CN104892477A (zh) * 2015-06-15 2015-09-09 尚科生物医药（上海）有限公司 手性2-甲基半胱氨酸及其盐酸盐的制备方法
MX2020009228A (es) 2018-03-08 2021-01-08 Incyte Corp Compuestos diolicos de aminopirazina como inhibidores de fosfoinositida 3-cinasas-gamma.
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668651A (en) 1985-09-05 1987-05-26 Union Carbide Corporation Transition metal complex catalyzed processes
CA2036770C (en) 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
US5132453A (en) 1991-03-22 1992-07-21 Cornell Research Foundation, Inc. N6 -(hydrazinoiminomethyl)lysine and method of inhibiting nitric oxide formation in body
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
EP0670720A1 (en) 1992-11-27 1995-09-13 The Wellcome Foundation Limited Enzyme inhibitors
WO1994014780A1 (en) 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
US5474955A (en) 1993-08-06 1995-12-12 Micron Technology, Inc. Method for optimizing thermal budgets in fabricating semconductors
ATE222100T1 (de) 1993-10-21 2002-08-15 Searle & Co Amidino-derivate nützlich als no synthase-hemmer
RU2136661C1 (ru) 1993-10-21 1999-09-10 Джи Ди Сирл энд Ко. Амидинопроизводные, их применение и фармацевтическая композиция
US5466823A (en) 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US6143790A (en) 1994-03-10 2000-11-07 G.D. Searle & Co. L-N6 -(1-iminoethyl)lysine derivatives useful as nitric oxide synthase inhibitors
AU2190895A (en) 1994-03-24 1995-10-09 G.D. Searle & Co. Amidino derivatives useful as nitric oxide synthase inhibitors
ATE229001T1 (de) * 1994-06-15 2002-12-15 Wellcome Found Zwischenprodukte verwendbar in der herstellung von enzym-inhibitoren
US5684008A (en) 1994-11-09 1997-11-04 G. D. Searle & Co. Aminotetrazole derivatives useful as nitric oxide synthase inhibitors
CA2216882A1 (en) 1995-04-20 1996-10-24 G.D. Searle & Co. Cyclic amidino agents useful as nitric oxide synthase inhibitors
CN1190390A (zh) 1995-05-10 1998-08-12 G.D.瑟尔公司 由环状脒衍生的氧化氮合成酶抑制剂
US5830917A (en) 1995-09-11 1998-11-03 G. D. Searle & Co. L-N6 -(1-iminoethyl) lysine derivatives useful as nitric oxide synthase inhibitors
US5945408A (en) 1996-03-06 1999-08-31 G.D. Searle & Co. Hydroxyanidino derivatives useful as nitric oxide synthase inhibitors
US5981511A (en) 1996-03-06 1999-11-09 G.D. Searle & Co. Hydroxyamidino derivatives useful as nitric oxide synthase inhibitors
HUP9901739A3 (en) 1996-04-13 2000-06-28 Astrazeneca Ab Aminoisoquinolines and aminothienopyridine derivatives, process for producing thereof and pharmaceutical compositions containing them
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.
US6077850A (en) 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US6034256A (en) 1997-04-21 2000-03-07 G.D. Searle & Co. Substituted benzopyran derivatives for the treatment of inflammation
SE9703693D0 (sv) * 1997-10-10 1997-10-10 Astra Pharma Prod Novel combination
AP2000001900A0 (en) 1998-03-11 2000-09-30 Searle & Co Halogeneted amidino amino acid derivatives useful as nitric oxide synthase inhibitors.
GB9811599D0 (en) 1998-05-30 1998-07-29 Glaxo Group Ltd Nitric oxide synthase inhibitors
SE9802333D0 (sv) * 1998-06-29 1998-06-29 Astra Pharma Prod Novel combination
JP2003512292A (ja) 1998-10-27 2003-04-02 アボット・ラボラトリーズ プロスタグランジンエンドペルオキシドｈシンターゼ生合成阻害剤
AU1308400A (en) 1998-10-30 2000-05-22 G.D. Searle & Co. Novel amino acid heterocyclic amide derivatives useful as nitric oxide synthase inhibitors
AU2847200A (en) * 1999-01-27 2000-08-18 G.D. Searle & Co. Novel hydroxyamidino carboxylate derivatives useful as nitric oxide synthase inhibitors
AU2661400A (en) * 1999-02-27 2000-09-21 Glaxo Group Limited Pyrazolopyridines
ZA200206459B (en) * 2000-03-24 2003-08-13 Pharmacia Corp Amidino compound and salts thereof useful as nitric oxide synthase inhibitors.
US6525051B2 (en) * 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
AR032318A1 (es) * 2000-04-13 2003-11-05 Pharmacia Corp Compuesto derivado halogenado del acido 2-amino-5,6 heptenoico; composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento util como inhibidor de la oxido nitrico sintetasa

Also Published As

Publication number Publication date
WO2002076395A2 (en) 2002-10-03
WO2002076395A3 (en) 2004-08-12
US20030013702A1 (en) 2003-01-16
JP2005500259A (ja) 2005-01-06
AU2002248693A2 (en) 2002-10-08
EA200300934A1 (ru) 2004-12-30
EP1463495A4 (en) 2005-11-16
CA2441394A1 (en) 2002-10-03
US7012098B2 (en) 2006-03-14
EP1463495A2 (en) 2004-10-06

Similar Documents

Publication Publication Date Title
IL251270A0 (en) Cancer treatment
AU6147401A (en) Compositions and methods for the treatment of cancer
GB2393202B (en) Methods of well treatment
PL370029A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
EP1355563A4 (en) METHODS OF PREVENTING AND TREATING CANCER WITH ANTI-C3B (I) ANTIBODIES
MXPA03008582A (es) Agentes y metodos para tratamiento de cancer.
HUP0500424A2 (en) Combination therapy for the treatment of cancer
EP1379242A4 (en) METHOD OF TREATING CANCERS AND APPROPRIATE COMPOSITIONS
EP1442062A4 (en) METHOD FOR TREATING CARCINOMA
IL158206A0 (en) Compositions and methods for the prevention and treatment of human prostate cancer
IL145397A0 (en) Compositions and methods for treatment of cancer
PL368035A1 (en) Compositions and methods for the treatment of cancer
GB2389532C (en) The method of treating cancer
MXPA03007036A (es) Metodo de terapia para cancer.
EP1401377A4 (en) CANCER TREATMENT METHODS
GB0124124D0 (en) Methods of treatment
AU2002366195A8 (en) Use of bisindolmaleimide and gemcitabine for the treatment of cancer
EP1423118A4 (en) METHOD AND COMPOSITION FOR CANCER TREATMENT
EP1409734A4 (en) DIAGNOSIS AND TREATMENT OF CANCER
ZA200203166B (en) Treatment of cancer.
EP1684795A4 (en) METHODS AND AGENTS FOR THE TREATMENT OF CANCER
IL161630A0 (en) Methods of treating endometreosis
AU2002360454A8 (en) Methods and compositions for treating cancer
IL160242A0 (en) Methods for the treatment and prognosis of leukemia and other cancer types
GB0115943D0 (en) Treatment and diagosis of cancer